Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 25, 2016 - Issue 10
Submit an article Journal homepage
427
Views
11
CrossRef citations to date
0
Altmetric
Review

The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes

K. PafiliDiabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, GreeceView further author information
,
E. MaltezosDiabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, GreeceView further author information
&
N. PapanasDiabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, GreeceCorrespondence[email protected]
View further author information
Pages 1133-1152 | Received 09 Jan 2016, Accepted 21 Jul 2016, Published online: 05 Aug 2016

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

K. Pafili & N. Papanas. (2019) Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?. Expert Review of Clinical Pharmacology 12:8, pages 693-695.
Read now
Kalliopi Pafili, Efstratios Maltezos & Nikolaos Papanas. (2018) Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?. Expert Opinion on Pharmacotherapy 19:3, pages 185-187.
Read now
Cheng Xiu, Zhou Hua, Bao sheng Xiao, Wen Jian Tang, Hai Pin Zhou & Xin Hua Liu. (2017) Novel benzopyran derivatives and their therapeutic applications: a patent review (2009–2016). Expert Opinion on Therapeutic Patents 27:9, pages 1031-1045.
Read now
Kalliopi Pafili, Efstratios Maltezos & Nikolaos Papanas. (2017) Dapagliflozin for the treatment of type 1 diabetes mellitus. Expert Opinion on Investigational Drugs 26:7, pages 873-881.
Read now

Articles from other publishers (7)

Jianlong Zhai, Zhongli Wang, Tingting Zhang, Lili He, Sai Ma, Qingjuan Zuo, Guorui Zhang, Xinyu Wang & Yifang Guo. (2023) Canagliflozin and irbesartan ameliorate renal fibrosis via the TGF-β1/Smad signaling pathway in Dahl salt-sensitive rats. Journal of International Medical Research 51:10.
Crossref
Zhenwang Zhang, Ping Ni, Mingqiu Tang, Yi Song, Chao Liu & Baoqing Zhao. (2023) Dapagliflozin alleviates renal podocyte pyroptosis via regulation of the HO‑1/NLRP3 axis. Molecular Medicine Reports 28:5.
Crossref
Krit Jaikumkao, Sasivimon Promsan, Laongdao Thongnak, Myat T. Swe, Monruedee Tapanya, Khin T. Htun, Suchart Kothan, Nuttawadee Intachai & Anusorn Lungkaphin. (2021) Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK/mTOR signaling pathway in obese rats. Journal of Cellular Physiology 236:9, pages 6424-6440.
Crossref
Kalliopi Pafili & Michael Roden. (2021) Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Molecular Metabolism 50, pages 101122.
Crossref
Fengjuan Huang, Yanyan Zhao, Qingzhu Wang, Jan-Luuk Hillebrands, Jacob van den Born, Linlin Ji, Tingting An & Guijun Qin. (2019) Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated With Type 1 Diabetes by Regulating STAT1/TGFβ1 Signaling. Frontiers in Endocrinology 10.
Crossref
Prashanth R. J. Vas, Periklis Panagopoulos & Nikolaos Papanas. (2018) Diabetic Foot Fungal Osteomyelitis: No Longer Unknown and Hidden?. The International Journal of Lower Extremity Wounds 17:3, pages 142-143.
Crossref
Zheng Li, Xue Xu, Liming Deng, Ruoxian Liao, Ruiying Liang, Bo Zhang & Luyong Zhang. (2018) Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents. Bioorganic & Medicinal Chemistry 26:14, pages 3947-3952.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.